

First-Quarter (April 1 – June 30, 2003) Flash Report (unaudited)

Three months ended June 30, 2003

ONO PHARMACEUTICAL CO., LTD.

August 6, 2003

1. Consolidated financial results for three months ended June 30, 2003

(1) Net sales

(Note) All yen amounts are rounded down to the nearest million yen.

	Millions of yen			Thousands of US\$
	First-Quarter 3 months ended June 30 2003	First-Quarter 3 months ended June 30 2002	Annual 12 months ended March 31 2003	First-Quarter 3 months ended June 30 2003
Net sales	¥ 36,334	¥ —	¥ 134,993	\$ 302,783

Note 1 First-Quarter Flash Report begins on April 1, 2003.

Note 2 U.S. Dollar amounts herein are given solely for the convenience of readers outside Japan and are stated, as a matter of arithmetical computation only, at the rate of Japanese yen 120 = US\$ 1, the approximate exchange rate prevailing on June 30, 2003.

[Supplementary explanation on the net sales]

Although a National Health Insurance (NHI) drug price revision was not implemented in the first quarter, the Japanese pharmaceutical industry labored under a continuing, harsh business climate associated with the government's enforcement of various medical cost-containment measures and intensified by market competition among Japanese and non-Japanese companies. Despite these circumstances, Ono Pharmaceutical Co., Ltd. and its subsidiaries achieved first quarter net sales of 36,334 million yen (US\$302,783 thousand) (52.8% progress against our semiannual forecast) as a result of energetic, scientific promotional activities, mainly at study and lecture meetings. These activities supported our major products: Onon® Capsule for bronchial asthma and allergic rhinitis; Onon® Dry Syrup for pediatric bronchial asthma; Opalmon® Tablet for improving peripheral circulatory disorders (In April 2001, Opalmon® was granted an additional indication for improving subjective symptoms such as pain and numbness of the legs and improving walking ability in patients with acquired lumbar canal stenosis); and Elaspol® 100 for Injection (launched in June 2002), the world's first drug for the treatment of acute lung injury associated with systemic inflammatory response syndrome (SIRS).

(2) The events which have material influence on financial position and business performance

There was no events for this First-Quarter.

2. Forecast of Consolidated financial results for the year ended March 31, 2004

(Note) All yen amounts are rounded down to the nearest million yen.

	Millions of yen		Thousands of US\$	
	Semi-annual 6 months ended Sep. 30 2003	Annual 12 months ended March 31 2004	Semi-annual 6 months ended Sep. 30 2003	Annual 12 months ended March 31 2004
Net sales	¥ 68,800	¥ 136,300	\$ 573,333	\$ 1,135,833
Net income	15,200	28,200	126,666	235,000
	Yen		US\$	
Net income per common share	¥ 128.99	¥ 239.32	\$ 1.07	\$ 1.99

Note U.S. Dollar amounts herein are given solely for the convenience of readers outside Japan and are stated, as a matter of arithmetical computation only, at the rate of Japanese yen 120 = US\$ 1, the approximate exchange rate prevailing on June 30, 2003.

First-Quarter (April 1 – June 30, 2003) Flash Report (unaudited)

Three months ended June 30, 2003

Ono Pharmaceutical Co., Ltd. and
Consolidated Subsidiaries

Sales of Major Products

Supplemental Data

For information purpose only

(Note) All amounts are rounded down to the nearest hundred million yen.

		Hundred Millions of yen			
		First-Quarter 3 months ended June 30 2003	First-Quarter 3 months ended June 30 2002	Annual 12 months ended March 31 2004(forecast)	
Kinedak	Agent for diabetic peripheral neuropathy	¥ 60	¥ —	¥ 239	
Onon	Agent for bronchial asthma and allergic rhinitis	62	—	235	
Opalmon	Circulatory system agent	56	—	210	
Foipan	Agent for chronic pancreatitis and postoperative reflux esophagitis	44	—	163	
Cataclot	Agent for (acute phase) cerebral thrombosis and cerebrovascular spasms	26	—	104	
Prostandin	Circulatory system agent	23	—	85	
FOY 500	Agent for DIC	16	—	67	
Onon Dry Syrup	Agent for pediatric bronchial asthma	14	—	55	
Elaspol	Acute lung injury associated with systemic inflammatory response syndrome	8	—	30	
Prostandin 500	Agent for perioperative hypotension	8	—	29	
FOY	Agent for pancreatitis and DIC	7	—	26	
Total		¥ 323	¥ —	¥ 1,246	
Percentage to total net sales		89%	— %	91%	

Note: First-Quarter Flash Report begins on April 1, 2003.

First-Quarter (April 1 – June 30, 2003) Flash Report (unaudited)

Three months ended June 30, 2003

Ono Pharmaceutical Co., Ltd. and
Consolidated Subsidiaries

Supplemental Information

Status of Major Developments

August 6, 2003

Developments in Japan

Awaiting manufacturing approval:

● **Prostandin® for Injection**

Alprostadil alfadex for patent ductus arteriosus associated with ductus arteriosus-dependent congenital heart diseases

Ongoing clinical studies:

New chemical entities:

● **Onobis™ Tablet (ONO-5920)**

Osteoporosis (tablet, Phase III)

● **Staybla® Tablet (ONO-8025) / KRP-197**

Hyperactive bladder (pollakiuria and urinary incontinence) (tablet, Phase III)

● **Proglia® for Injection (ONO-2506)**

Acute ischemic stroke (injection, Phase II)

● **ONO-4819-CD**

Vertebral fracture (injection, Phase II)

● **ONO-6126**

Bronchial asthma (tablet, Phase II)

● **Cereact® Capsule (ONO-2506PO)**

Parkinson's disease (capsule, Phase II under preparation)

● **ONO-8815Ly**

Imminent premature labor (injection, Phase I completed)

● **ONO-4817**

Inflammatory bowel disease and osteoarthritis (tablet, Phase I)

● **ONO-8130**

Hyperactive bladder (pollakiuria and urinary incontinence) (tablet, Phase I under preparation)

● **ONO-5129**

Diabetes (tablet, Phase I under preparation)

Ongoing clinical studies:

Additional indications:

● **Onoact® 50 for Injection (ONO-1101)**

Landirolol hydrochloride for post-operative tachyarrhythmia (Phase II/III)

● **Onon® Dry Syrup**

Pranlukast hydrate for pediatric allergic rhinitis (Phase II/III)

● **Onon® Capsule**

Pranlukast hydrate for chronic sinusitis and chronic obstructive pulmonary disease (Phase II)

Developments abroad

Ongoing clinical studies:

● **Proglia® for Injection (ONO-2506)**

Acute ischemic stroke (injection, Phase II)

● **Cereact® Capsule (ONO-2506PO)**

Alzheimer's disease and amyotrophic lateral sclerosis (ALS) (capsule, Phase II)

● **ONO-6126**

Bronchial asthma and chronic obstructive pulmonary disease (tablet, Phase II)

● **ONO-8815Ly**

Imminent premature labor (injection, Clinical pharmacology study completed)

● **ONO-4817**

Inflammatory bowel disease and osteoarthritis (tablet, Phase I completed)

● **ONO-4128 (GW873140)**

HIV/AIDS (tablet, Phase I)

● **ONO-4127Na**

Allergic rhinitis (tablet, Phase I)

● **ONO-8130**

Hyperactive bladder (pollakiuria and urinary incontinence) (tablet, Phase I under preparation)

● **ONO-5129**

Diabetes (tablet, Phase I under preparation)